Ovarian carcinosarcoma (a literature review)
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.295
Abstract
Introduction. Despite that ovarian carcinosarcoma (OCS) is an extremely rare disease, it is of great medical and social importance by taking into account very high level of overall mortality, recurrence, metastasis, and economic costs.
Aim: to summarize current data on various aspects of OCS.
Materials and Methods. The search strategy for English written papers published in databases PubMed/MEDLINE, Scopus, Web of Science, Google Scholar was based on the following keyword queries: «ovarian carcinosarcoma», «etiology and pathogenesis», «epidemiology», «classification», «clinical picture», «diagnosis», «treatment». The search depth was limited within the years 2010–2022, by prioritizing the search depth within the last 5 years (2017–2022).
Results. We found 48 articles in English, published from 2016 to 2022, of which 47 (97.9 %) articles were published within the last 5 years. Scientific data are represented by studies with a small patient sample and with low evidence base. The results of the analysis for identified publications showed a limited, fragmented and inconsistent scientific data both in terms of etiology, pathogenesis and treatment, as well as an impact of OCS stages, age and other risk factors on the likelihood of relapses.
Conclusion. The lack of extensive clinical studies along with observed substantial number of controversial issues may be accounted for by OCS low prevalence and complex pathogenesis. Nevertheless, the results obtained during the generalization of scientific knowledge provide a realistic insight into the current state of global science about this medical and social disease and may be used to improve the diagnostics and treatment of OCS patients.
About the Authors
A. M. Beishembaev
Daniyarov Kyrgyz State Medical Institute of Advanced Training and Retraining
Kyrgyzstan
Kyrgyzstan
Almaz М. Beishembaev – MD, PhD, Head of the Department of Oncology, Hematology, Radiation Diagnostics and Therapy, Faculty of Advanced Medical Education
720064, Bishkek, Bokonbaev Str., 144а
K. I. Zhordania
Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Kirill I. Zhordania – MD, Dr Sci Med, Gynecologist-Oncologist, Leading Researcher, Department of Gynecology
115478, Moscow, Kashirskoe Highway, 24
E. D. Choi
International Medical University
Kyrgyzstan
Kyrgyzstan
En D. Choi – MD, Dr Sci Med, Acting Associate Professor, Department of Surgical and Special Clinical Disciplines
720000, Bishkek, Ankara Str., 1/17
A. A. Turkmenov
Akhunbaev Kyrgyz State Medical Academy
Kyrgyzstan
Kyrgyzstan
Alybek А. Turkmenov – MD, PhD, Acting Associate Professor, Department of Propaedeutic Surgery
720020, Bishkek, Akhunbaev Str., 92
A. K. Moldobekova
Tentishev Asian Medical Institute
Kyrgyzstan
Kyrgyzstan
Aiperi K. Moldobekova – MD, Assistant, Department of Surgical Disciplines
Kant, Gagarin Str., 58
References
1. Gotoh O., Sugiyama Y., Takazawa Y. et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10(1):4965. https://doi.org/10.1038/s41467-019-12985-x.
2. Rottmann D., Snir O.L., Wu X. et al. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol. 2020;33(1):118–27. https://doi.org/10.1038/s41379-019-0358-x.
3. Gupta K.K., Gupta V.K., Naumann R.W. Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019;29(1):195–200. https://doi.org/10.1136/ijgc-2018-000016.
4. Xu Q., Zhang X., Zou Y. Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases. J Ovarian Res. 2020;13(1):129. https://doi.org/10.1186/s13048-020-00728-2.
5. Yue X., Pruemer J.M., Hincapie A.L. et al. Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014. J Gynecol Oncol. 2020;31(4):e52. https://doi.org/10.3802/jgo.2020.31.e52.
6. Delgado-Ortega L., Rubió J.G., de España M.C. et al. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain. Farm Hosp. 2018;42(3):95–102. https://doi.org/10.7399/fh.10904.
7. Bellone S., Buza N., Choi J. et al. Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clin Cancer Res. 2018;24(14):3282–91. https://doi.org/10.1158/1078-0432.CCR-17-1805.
8. Zhu J., Wen H., Ju X. et al. Clinical significance of programmed death ligand-1 and intra-tumoral CD8+ T-lymphocytes in ovarian carcinosarcoma. PLoS One. 2017;12(1):e0170879. https://doi.org/10.1371/journal.pone.017087.
9. Magalhaes I., Fernebro J., Own S.A. et al. Mesothelin expression in patients with high-grade serous ovarian cancer does not predict clinical outcome but correlates with CD11c+ expression in tumor. Adv Ther. 2020;37(12):5023–31. https://doi.org/10.1007/s12325-020-01520-w.
10. Li Y., Wang Q., Ning N. et al. Bioinformatic analysis reveals MIR502 as a potential tumour suppressor in ovarian cancer. J Ovarian Res. 2020;13(1):77. https://doi.org/10.1186/s13048-020-00683-y.
11. Cheng J., Guo J., Wang Z. et al. Functional analysis of Cullin 3 E3 ligases in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2018;1869(1):11–28. https://doi.org/10.1016/j.bbcan.2017.11.001
12. Smebye M.L., Agostini A., Johannessen B. et al. Involvement of DPP9 in gene fusions in serous ovarian carcinoma. BMC Cancer. 2017;17(1):642. https://doi.org/10.1186/s12885-017-3625-6.
13. Kostov S., Kornovski Y., Ivanova Y. et al. Ovarian carcinosarcoma with retroperitoneal para-aortic lymph node dissemination followed by an unusual postoperative complication: A case report with a brief literature review. Diagnostics (Basel). 2020;10(12):1073. https://doi.org/10.3390/diagnostics10121073.
14. Dal Molin G.Z., Abrahão C.M., Coleman R.L., Maluf F.C. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. Gynecol Oncol Res Pract. 2018;5(1):6. https://doi.org/10.1186/s40661-018-0063-3.
15. Cortez A.J., Tudrej P., Kujawa K.A., Lisowska K.M. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38. https://doi.org/10.1007/s00280-017-3501-8.
16. Nizam A., Bustamante B., Shan W. et al. Overall survival and adjuvant therapy in women with ovarian carcinosarcoma: A single-institution experience. Diagnostics (Basel). 2019;9(4):200. https://doi.org/10.3390/diagnostics9040200.
17. Zsiros E., Lynam S., Attwood K.M. et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7(1):78–85. https://doi.org/10.1001/jamaoncol.2020.5945.
18. Bardia A., Mayer I.A., Vahdat L.T. et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51. https://doi.org/10.1056/NEJMoa1814213.
19. Nishikawa T., Hasegawa K., Yabuno A. et al. Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. J Gynecol Oncol. 2017;28(1):e25. https://doi.org/10.3802/jgo.2017.28.e25.
20. Lopez S., Perrone E., Bellone S. et al. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget. 2020;11(5):560–70. https://doi.org/10.18632/oncotarget.27342.
21. Penson R.T., Valencia R.V., Cibula D. et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38(11):1164–74. https://doi.org/10.1200/JCO.19.02745.
22. Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287–99. https://doi.org/10.2147/IJWH.S197604.
23. Ni J., Zhou R., Cheng X. et al. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. J Ovarian Res. 2020;13(1):29. https://doi.org/10.1186/s13048-020-00629-4.
24. Zhao S., Bellone S., Lopez S. et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialmesenchymal transition. Proc Natl Acad Sci U S A. 2016;113(43):12238–43. https://doi.org/10.1073/pnas.1614120113.
25. Boussios S., Karathanasi A., Zakynthinakis-Kyriakou, N. et al. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol. 2019;134:46–55. https://doi.org/10.1016/j.critrevonc.2018.12.006.
26. Kim H.J., Lee H.-M., Kim M.K. et al. Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. Obstet Gynecol Sci. 2017;60(4):350–56. https://doi.org/10.5468/ogs.2017.60.4.350.
27. Han C.Y., Patten D.A., Richardson R.B. et al. Tumor metabolism regulating chemosensitivity in ovarian cancer. Genes Cancer. 2018;9(5–6):155–75. https://doi.org/10.18632/genesandcancer.176.
28. Lv J., Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019;7:18. https://doi.org/10.1186/s40364-019-0169-8.
29. Weidemann S., Gagelmann P., Gorbokon N. et al. Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors. Biomedicines. 2021;9(4):397. https://doi.org/10.3390/biomedicines9040397.
30. Klampatsa A., Dimou V., Albelda S.M. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21(4):473–86. https://doi.org/10.1080/14712598.2021.1843628.
31. Zhang Q., Liu G., Liu J. et al. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556–68. https://doi.org/10.1016/j.omto.2021.02.013.
32. Tokatlian T., Asuelime G.E., Mock J.-Y. et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer. 2022;10(1):e003826. https://doi.org/10.1136/jitc-2021-003826.
33. Shen J., Sun X., Zhou J. Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Front Oncol. 2020;10:1263. https://doi.org/10.3389/fonc.2020.01263.
34. Yang W., Ma J., Zhou W. et al. Reciprocal regulations between miRNAs and HIF-1alpha in human cancers. Cell Mol Life Sci. 2019;76(3):453–71. https://doi.org/10.1007/s00018-018-2941-6.
35. Melnik S., Werth N., Boeuf S. et al. Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells. Stem Cell Res Ther. 2019;10(1):73. https://doi.org/10.1186/s13287-019-1187-z.
36. Xu Z., Li L., Qian Y. et al. Upregulation of IL-6 in CUL4B-deficient myeloidderived suppressive cells increases the aggressiveness of cancer cells. Oncogene. 2019;38(30):5860–72. https://doi.org/10.1038/s41388-019-0847-x.
37. Duan P.J., Zhao J.H., Xie L.L. Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1. J Ovarian Res. 2020;13(1):76. https://doi.org/10.1186/s13048-020-00677-w.
38. Hutter C., Zenklusen J.C. The Cancer Genome Atlas: creating lasting value beyond its data. Cell. 2018;173(2):283–5. https://doi.org/10.1016/j.cell.2018.03.042.
39. Daimon A., Fujiwara S., Tanaka Y. et al. A rare case of ovarian carcinosarcoma with squamous cell carcinoma. J Ovarian Res. 2019;12(1):32. https://doi.org/10.1186/s13048-019-0507-3.
40. Niwa K., Mori S., Kuwabara K. et al. Primary ovarian carcinosarcoma: cytological, pathological, immunocytochemical, and immunohistochemical features. Open J Pathol, 2021;11:22–31. https://doi.org/10.4236/ojpathology.2021.111003.
41. Sroczynski G., Gogollari A., Kuehne F. et al. A systematic review on costeffectiveness studies evaluating ovarian cancer early detection and prevention strategies. Cancer Prev Res (Phila). 2020;13(5):429–42. https://doi.org/10.1158/1940-6207.CAPR-19-0506.
42. Li X., Xu Y., Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:265–76. https://doi.org/10.1016/bs.pmbts.2019.01.005.
43. Goldenberg D.M., Stein R., Sharkey R.M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–9006. https://doi.org/10.18632/oncotarget.25615.
44. Gulia S., Ghosh J., Bajpai J. et al. Pazopanib and oral cyclophosphamide in women with platinum-resistant or -refractory epithelial ovarian cancer. JCO Glob Oncol. 2020;6:542–7. https://doi.org/10.1200/JGO.19.00331.
45. Varga A., Piha-Paul S.A., Ott P.A. et al. Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. J Clin Oncol. 2017;35(15 Suppl):5513. https://doi.org/10.1200/JCO.2017.35.15_suppl.5513.
46. Matulonis U.A., Shapira-Frommer R., Santin A.D. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–87. https://doi.org/10.1093/annonc/mdz135.
47. Gray J.E., Heist R.S., Starodub A.N. et al. Therapy of small cell Lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23(19):5711–19. https://doi.org/10.1158/1078-0432.CCR-17-0933.
48. Heist R.S., Guarino M.J., Masters G. et al. Therapy of advanced non-smallcell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35(24):2790–97. https://doi.org/10.1200/JCO.2016.72.1894.
Review
For citations:
Beishembaev A.M., Zhordania K.I., Choi E.D., Turkmenov A.A., Moldobekova A.K. Ovarian carcinosarcoma (a literature review). Obstetrics, Gynecology and Reproduction. 2022;16(5):575-587. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.295
Views:
1404
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
